List of Antibodies Companies in Oregon - 4

AgonOx, Inc.is a spin-off company from the Providence Cancer Center located in Portland, Oregon. We are developing immune system activators for use in cancer therapy. Research in the field of T-cell modulation conducted worldwide with OX40 and other agents has demonstrated that the use of T-cell modulating therapies in combination with specific anti-tumor therapies have the potential for yielding therapeutic benefits for patients with cancer. AgonOx is focused on the development of immune system modulators in combination with other promising agents in the immune oncology space.

Aronora is a translational biotechnology company (aronorabio.com) engaged in the development of proprietary biologic therapeutics, including recombinant monolconal antibodies and enzymes. Rational design of our innovative therapeutic agents is expected to result in drug products that reduce the progression and growth of life-threatening blood clots without the detrimental bleeding side effects that characterize all currently marketed antithrombotic drugs. Our products are intended to be used in difficult-to-treat, severe, rapidly progressing, or catastrophic thrombotic blood clotting diseases.

PDX Pharmaceuticals is an IND-enabling stage biopharmaceutical company. We develop novel combination and immunotherapies to treat cancer by bringing complementary biological pathways together to achieve synergistic clinical benefit. Our therapeutic candidates bridge the innate and adaptive immune systems by generating profound CD8+ T cell production. Our pipelines are patented AIRISE (Augmenting Immune Responses and Inhibiting the Suppressive Environment of Tumors) and ARAC (Antigen Release Agent and Checkpoint Inhibitor) pipelines that generate anti-tumor immunity when given locally (AIRISE) or systemically (ARAC) by relying on patient' s own tumor in situ as the source of antigens.

Sedia Biosciences is a privately held medical device and diagnostics company founded in 2009 and based in Portland Oregon. Our commitment is to become a leader in three areas intended to advance global access to care as reflected by our: (1) expertise in rapid point of care diagnostic assays, especially alternative fluid (e.g. oral, urine, etc) assays, (2) scientific and market leadership in novel HIV epidemiological disease incidence assays and other public health tools and (3) novel clinical specimen collection devices to improve and facilitate remote collection of specimens for follow-up testing. Sedia brings together a dedicated team of researchers, scientists and business people that share our common mission and develops, manufactures and licenses these technology and products to improve access to medical care around the world.